Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Immune potentiation to improve neonatal and pediatric vaccines

Award Number: R03AI117700
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2015
PERIOD OF PERFORMANCE END DATE: 04/30/2017

Group Awards By:

View Award Description

Immune potentiation to improve neonatal and pediatric vaccines - ¿ DESCRIPTION (provided by applicant): Immune potentiation to improve neonatal and pediatric vaccines Abstract: Neonatal and infant immune responses are generally weak and biased against a Th1 response making these vulnerable populations susceptible to multiple infectious diseases. The majority of infant deaths occur in the first six months of life due to vaccine preventable bacterial or viral respiratory or diarrheal infectious diseases. Early immunization is required to protect infants but is limited by the immaturity of the immune system. Innate immunity is central to all immunity as it instructs adaptive immunity to subsequently generate immune memory. Methods to overcome the innate immune deficit at birth have been long sought. Although there are intrinsic defects in neonatal B and T cells, it has been shown by our group and others that in vitro addition of adult antigen presenting cells (APCs) can restore antigen specific B- and T cell activation/memory responses in neonates. In preliminary work for this application we have determined that the central defect in neonatal immune responses may reside in APC function. Based on our recent findings we hypothesize that identification of antigen-agonist-adjuvant combinations that will induce optimum neonatal DC activation and function will improve vaccine responsiveness that may pave the way for novel modifications resulting in effective neonatal and pediatric vaccination. We will focus on TLR agonist-adjuvant (MF59) combinations to stimulate neonatal APC cells and compare results to 5-year old children (before and after booster vaccinations) and to adults. In order to demonstrate immune potentiation by incorporation of stronger TLR agonist-MF59 combination in a vaccine perspective, we will compare immunogenicity of genetically detoxified acellular pertussis toxoid to a less immunogenic, chemically detoxified pertussis toxoid (currently widely used in DTaP or TDaP) in neonates, 5 year olds and adults. The findings of this project will represent major public health significance for neonatal/ infant vaccinations as well as improving booster vaccinations.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2017 ( Subtotal = $0 )
2017	2016	ROCHESTER GENERAL HOSPITAL, THE	1425 PORTLAND AVE	ROCHESTER	NY	14621	MONROE	USA	Allergy and Infectious Diseases Research	000	2	9/14/2017	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2016 ( Subtotal = $80,000 )
2016	2016	ROCHESTER GENERAL HOSPITAL	1425 PORTLAND AVENUE	ROCHESTER	NY	14621	MONROE	USA	Allergy and Infectious Diseases Research	000	2	4/4/2016	NON-COMPETING CONTINUATION	$80,000
2016	2016	ROCHESTER GENERAL HOSPITAL	1425 PORTLAND AVENUE	ROCHESTER	NY	14621	MONROE	USA	Allergy and Infectious Diseases Research	001	2	5/4/2016	NON-COMPETING CONTINUATION	$0
														Subtotal = $80,000

Issue Date FY: 2015 ( Subtotal = $80,000 )
2015	2015	ROCHESTER GENERAL HOSPITAL	1425 PORTLAND AVENUE	ROCHESTER	NY	14621	MONROE	USA	Allergy and Infectious Diseases Research	000	1	4/24/2015	NEW	$80,000
														Subtotal = $80,000

Grand Total All Awards = $160,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Immune potentiation to improve neonatal and pediatric vaccines

Award Number: R03AI117700

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2015

PERIOD OF PERFORMANCE END DATE: 04/30/2017

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer